Navigation Links
AstraZeneca and Abbott End License Agreement for the Development of CERTRIAD

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.  

A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on March 30, 2010.

The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.  

AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.


About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009.  In the United States, AstraZeneca is a $14.8 billion healthcare business.   

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: or call 1-800-AZandMe (292-6363).

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... November 25, 2015 Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ... and regulatory/legal strategies all play a key role ... GBI Research . --> Developmental, ... key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... Abington Hospital – Jefferson Health is ... Bariatric Surgery Facility for treating individuals living with morbid or extreme obesity. , ... to its members to help them make informed decisions about their healthcare needs. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered ... venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea ... opened a Koala Center for Sleep Disorders in the US, one of four in the ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health ... have announced their endorsement of the Medical Fitness Network (MFN), a national ... to have the MFN as one of our endorsed organizations,” said ASH Fitness ...
(Date:11/24/2015)... ... , ... Autism Speaks, the world’s leading autism science and advocacy organization, will ... generosity of people around the world. On December 1, supporters can make an online ... share the personal stories behind those gifts. , Just as Black Friday and ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... engineer of patented products, announces Innovative Blending, a household invention that revolutionizes the ... "The Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, ...
Breaking Medicine News(10 mins):